nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Cardio-respiratory arrest—Vandetanib—thyroid cancer	0.0491	0.0783	CcSEcCtD
Metoclopramide—Altered state of consciousness—Vandetanib—thyroid cancer	0.038	0.0606	CcSEcCtD
Metoclopramide—Sunitinib—RET—thyroid cancer	0.0278	1	CrCbGaD
Metoclopramide—Suicide—Sorafenib—thyroid cancer	0.0228	0.0364	CcSEcCtD
Metoclopramide—Completed suicide—Sorafenib—thyroid cancer	0.0201	0.0321	CcSEcCtD
Metoclopramide—Respiratory failure—Vandetanib—thyroid cancer	0.0179	0.0285	CcSEcCtD
Metoclopramide—Atrial fibrillation—Vandetanib—thyroid cancer	0.0134	0.0214	CcSEcCtD
Metoclopramide—Cardiac arrest—Vandetanib—thyroid cancer	0.0121	0.0193	CcSEcCtD
Metoclopramide—Bronchospasm—Vandetanib—thyroid cancer	0.0108	0.0173	CcSEcCtD
Metoclopramide—Gynaecomastia—Sorafenib—thyroid cancer	0.0106	0.0169	CcSEcCtD
Metoclopramide—Neutropenia—Vandetanib—thyroid cancer	0.0103	0.0164	CcSEcCtD
Metoclopramide—Pollakiuria—Vandetanib—thyroid cancer	0.0102	0.0162	CcSEcCtD
Metoclopramide—Depression—Vandetanib—thyroid cancer	0.00978	0.0156	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Sorafenib—thyroid cancer	0.00947	0.0151	CcSEcCtD
Metoclopramide—Bradycardia—Vandetanib—thyroid cancer	0.00896	0.0143	CcSEcCtD
Metoclopramide—Visual impairment—Vandetanib—thyroid cancer	0.00848	0.0135	CcSEcCtD
Metoclopramide—Muscle spasms—Vandetanib—thyroid cancer	0.00737	0.0118	CcSEcCtD
Metoclopramide—Tremor—Vandetanib—thyroid cancer	0.00718	0.0115	CcSEcCtD
Metoclopramide—Neutropenia—Sorafenib—thyroid cancer	0.00694	0.0111	CcSEcCtD
Metoclopramide—Erectile dysfunction—Sorafenib—thyroid cancer	0.00683	0.0109	CcSEcCtD
Metoclopramide—Convulsion—Vandetanib—thyroid cancer	0.00664	0.0106	CcSEcCtD
Metoclopramide—Hypertension—Vandetanib—thyroid cancer	0.00662	0.0106	CcSEcCtD
Metoclopramide—Anxiety—Vandetanib—thyroid cancer	0.0065	0.0104	CcSEcCtD
Metoclopramide—Jaundice—Sorafenib—thyroid cancer	0.00645	0.0103	CcSEcCtD
Metoclopramide—Oedema—Vandetanib—thyroid cancer	0.00625	0.00998	CcSEcCtD
Metoclopramide—Insomnia—Vandetanib—thyroid cancer	0.00566	0.00903	CcSEcCtD
Metoclopramide—Dyspnoea—Vandetanib—thyroid cancer	0.00558	0.0089	CcSEcCtD
Metoclopramide—Flushing—Sorafenib—thyroid cancer	0.00551	0.0088	CcSEcCtD
Metoclopramide—Fatigue—Vandetanib—thyroid cancer	0.00539	0.00861	CcSEcCtD
Metoclopramide—Blood disorder—Epirubicin—thyroid cancer	0.00523	0.00835	CcSEcCtD
Metoclopramide—Delirium—Epirubicin—thyroid cancer	0.00508	0.00811	CcSEcCtD
Metoclopramide—Amenorrhoea—Epirubicin—thyroid cancer	0.00497	0.00794	CcSEcCtD
Metoclopramide—Muscle spasms—Sorafenib—thyroid cancer	0.00497	0.00793	CcSEcCtD
Metoclopramide—Body temperature increased—Vandetanib—thyroid cancer	0.00494	0.00789	CcSEcCtD
Metoclopramide—Blood disorder—Doxorubicin—thyroid cancer	0.00484	0.00773	CcSEcCtD
Metoclopramide—Angioedema—Sorafenib—thyroid cancer	0.00472	0.00754	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—thyroid cancer	0.0047	0.0075	CcSEcCtD
Metoclopramide—Dyskinesia—Epirubicin—thyroid cancer	0.00465	0.00742	CcSEcCtD
Metoclopramide—Leukopenia—Sorafenib—thyroid cancer	0.00463	0.00739	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—thyroid cancer	0.0046	0.00735	CcSEcCtD
Metoclopramide—Atrioventricular block—Epirubicin—thyroid cancer	0.00451	0.00719	CcSEcCtD
Metoclopramide—Asthenia—Vandetanib—thyroid cancer	0.00449	0.00716	CcSEcCtD
Metoclopramide—Hypertension—Sorafenib—thyroid cancer	0.00446	0.00712	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Epirubicin—thyroid cancer	0.00437	0.00698	CcSEcCtD
Metoclopramide—Dyskinesia—Doxorubicin—thyroid cancer	0.0043	0.00687	CcSEcCtD
Metoclopramide—Diarrhoea—Vandetanib—thyroid cancer	0.00428	0.00683	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—thyroid cancer	0.00417	0.00665	CcSEcCtD
Metoclopramide—Fluid retention—Epirubicin—thyroid cancer	0.00415	0.00662	CcSEcCtD
Metoclopramide—Dizziness—Vandetanib—thyroid cancer	0.00414	0.0066	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00404	0.00646	CcSEcCtD
Metoclopramide—Rash maculo-papular—Epirubicin—thyroid cancer	0.00397	0.00634	CcSEcCtD
Metoclopramide—Rash—Vandetanib—thyroid cancer	0.00394	0.00629	CcSEcCtD
Metoclopramide—Dermatitis—Vandetanib—thyroid cancer	0.00394	0.00629	CcSEcCtD
Metoclopramide—Headache—Vandetanib—thyroid cancer	0.00392	0.00625	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—thyroid cancer	0.00384	0.00613	CcSEcCtD
Metoclopramide—Dyspnoea—Sorafenib—thyroid cancer	0.00376	0.006	CcSEcCtD
Metoclopramide—Nausea—Vandetanib—thyroid cancer	0.00372	0.00593	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00368	0.00587	CcSEcCtD
Metoclopramide—Fatigue—Sorafenib—thyroid cancer	0.00364	0.00581	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—thyroid cancer	0.0035	0.00558	CcSEcCtD
Metoclopramide—Urticaria—Sorafenib—thyroid cancer	0.00335	0.00535	CcSEcCtD
Metoclopramide—Body temperature increased—Sorafenib—thyroid cancer	0.00334	0.00532	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—thyroid cancer	0.00333	0.00532	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00324	0.00517	CcSEcCtD
Metoclopramide—Hypersensitivity—Sorafenib—thyroid cancer	0.00311	0.00496	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—thyroid cancer	0.00308	0.00492	CcSEcCtD
Metoclopramide—Asthenia—Sorafenib—thyroid cancer	0.00303	0.00483	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—thyroid cancer	0.00302	0.00482	CcSEcCtD
Metoclopramide—Diarrhoea—Sorafenib—thyroid cancer	0.00289	0.00461	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—thyroid cancer	0.00279	0.00446	CcSEcCtD
Metoclopramide—Dizziness—Sorafenib—thyroid cancer	0.00279	0.00445	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—thyroid cancer	0.00274	0.00438	CcSEcCtD
Metoclopramide—Rash—Sorafenib—thyroid cancer	0.00266	0.00425	CcSEcCtD
Metoclopramide—Dermatitis—Sorafenib—thyroid cancer	0.00266	0.00424	CcSEcCtD
Metoclopramide—Headache—Sorafenib—thyroid cancer	0.00264	0.00422	CcSEcCtD
Metoclopramide—Neutropenia—Epirubicin—thyroid cancer	0.00256	0.00409	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—thyroid cancer	0.00254	0.00405	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—thyroid cancer	0.00253	0.00404	CcSEcCtD
Metoclopramide—Nausea—Sorafenib—thyroid cancer	0.00251	0.004	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—thyroid cancer	0.00244	0.0039	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—thyroid cancer	0.00238	0.0038	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—thyroid cancer	0.00237	0.00379	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—thyroid cancer	0.00234	0.00374	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—thyroid cancer	0.00228	0.00364	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—thyroid cancer	0.00226	0.00361	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—thyroid cancer	0.00223	0.00357	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—thyroid cancer	0.00221	0.00352	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—thyroid cancer	0.00212	0.00338	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—thyroid cancer	0.00211	0.00337	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—thyroid cancer	0.00207	0.0033	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—thyroid cancer	0.00204	0.00325	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—thyroid cancer	0.00196	0.00312	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—thyroid cancer	0.00188	0.00301	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—thyroid cancer	0.00186	0.00296	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—thyroid cancer	0.00184	0.00293	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—thyroid cancer	0.00176	0.0028	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—thyroid cancer	0.00172	0.00274	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—NDUFA13—thyroid cancer	0.00171	0.00495	CbGpPWpGaD
Metoclopramide—Leukopenia—Epirubicin—thyroid cancer	0.00171	0.00273	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—TRIM33—thyroid cancer	0.00171	0.00494	CbGpPWpGaD
Metoclopramide—Muscle spasms—Doxorubicin—thyroid cancer	0.0017	0.00271	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—thyroid cancer	0.00169	0.00269	CcSEcCtD
Metoclopramide—DRD2—GPCR ligand binding—CALCB—thyroid cancer	0.00166	0.0048	CbGpPWpGaD
Metoclopramide—Convulsion—Epirubicin—thyroid cancer	0.00166	0.00264	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—thyroid cancer	0.00165	0.00263	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—thyroid cancer	0.00162	0.00259	CcSEcCtD
Metoclopramide—CHRM1—GPCR ligand binding—CALCB—thyroid cancer	0.00162	0.0047	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—MINPP1—thyroid cancer	0.00162	0.00469	CbGpPWpGaD
Metoclopramide—Anxiety—Epirubicin—thyroid cancer	0.00162	0.00259	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—CHST14—thyroid cancer	0.00161	0.00466	CbGpPWpGaD
Metoclopramide—Leukopenia—Doxorubicin—thyroid cancer	0.00158	0.00253	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—thyroid cancer	0.00157	0.00251	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—thyroid cancer	0.00156	0.00249	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—thyroid cancer	0.00156	0.00249	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00156	0.00451	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—CP—thyroid cancer	0.00156	0.00451	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—TSHR—thyroid cancer	0.00155	0.00449	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00153	0.00443	CbGpPWpGaD
Metoclopramide—Convulsion—Doxorubicin—thyroid cancer	0.00153	0.00244	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—thyroid cancer	0.00153	0.00244	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—thyroid cancer	0.00152	0.00243	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—thyroid cancer	0.0015	0.00239	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—NDUFA13—thyroid cancer	0.00148	0.00427	CbGpPWpGaD
Metoclopramide—Hypotension—Epirubicin—thyroid cancer	0.00146	0.00233	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—thyroid cancer	0.00145	0.00232	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—thyroid cancer	0.00144	0.0023	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—TSHR—thyroid cancer	0.00141	0.00408	CbGpPWpGaD
Metoclopramide—Insomnia—Epirubicin—thyroid cancer	0.00141	0.00225	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—thyroid cancer	0.00141	0.00225	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—thyroid cancer	0.00139	0.00222	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00139	0.00401	CbGpPWpGaD
Metoclopramide—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00139	0.00401	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CHST14—thyroid cancer	0.00139	0.00401	CbGpPWpGaD
Metoclopramide—Somnolence—Epirubicin—thyroid cancer	0.00139	0.00221	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—NDUFA13—thyroid cancer	0.00138	0.00399	CbGpPWpGaD
Metoclopramide—Hypotension—Doxorubicin—thyroid cancer	0.00135	0.00215	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—thyroid cancer	0.00134	0.00215	CcSEcCtD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00132	0.00381	CbGpPWpGaD
Metoclopramide—Insomnia—Doxorubicin—thyroid cancer	0.0013	0.00208	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—HPGD—thyroid cancer	0.0013	0.00375	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CHST14—thyroid cancer	0.0013	0.00375	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—SST—thyroid cancer	0.00129	0.00373	CbGpPWpGaD
Metoclopramide—Dyspnoea—Doxorubicin—thyroid cancer	0.00129	0.00205	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—thyroid cancer	0.00128	0.00205	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—thyroid cancer	0.00128	0.00205	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—thyroid cancer	0.00124	0.00199	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—thyroid cancer	0.00124	0.00198	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—thyroid cancer	0.00123	0.00197	CcSEcCtD
Metoclopramide—DRD3—GPCR downstream signaling—CALCB—thyroid cancer	0.00123	0.00354	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—SST—thyroid cancer	0.00121	0.00349	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—PTCH1—thyroid cancer	0.0012	0.00347	CbGpPWpGaD
Metoclopramide—Feeling abnormal—Doxorubicin—thyroid cancer	0.00119	0.0019	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00117	0.00337	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CALCA—thyroid cancer	0.00116	0.00336	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Epirubicin—thyroid cancer	0.00115	0.00183	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—thyroid cancer	0.00115	0.00183	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—thyroid cancer	0.00114	0.00182	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—TCF7L1—thyroid cancer	0.00114	0.00329	CbGpPWpGaD
Metoclopramide—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00112	0.00325	CbGpPWpGaD
Metoclopramide—Asthenia—Epirubicin—thyroid cancer	0.00112	0.00179	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—HPGD—thyroid cancer	0.00112	0.00323	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CALCB—thyroid cancer	0.00111	0.00322	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—SST—thyroid cancer	0.0011	0.00317	CbGpPWpGaD
Metoclopramide—Diarrhoea—Epirubicin—thyroid cancer	0.00107	0.0017	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—thyroid cancer	0.00106	0.0017	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—CALCA—thyroid cancer	0.00106	0.00305	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00105	0.00304	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—HPGD—thyroid cancer	0.00105	0.00303	CbGpPWpGaD
Metoclopramide—Asthenia—Doxorubicin—thyroid cancer	0.00104	0.00165	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—thyroid cancer	0.00103	0.00165	CcSEcCtD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00103	0.00297	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00101	0.00292	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—TSHR—thyroid cancer	0.001	0.0029	CbGpPWpGaD
Metoclopramide—Diarrhoea—Doxorubicin—thyroid cancer	0.000987	0.00158	CcSEcCtD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000987	0.00286	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—SST—thyroid cancer	0.000987	0.00285	CbGpPWpGaD
Metoclopramide—Rash—Epirubicin—thyroid cancer	0.000983	0.00157	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—thyroid cancer	0.000982	0.00157	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00098	0.00283	CbGpPWpGaD
Metoclopramide—Headache—Epirubicin—thyroid cancer	0.000977	0.00156	CcSEcCtD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—AKT1—thyroid cancer	0.000973	0.00281	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CDK1—thyroid cancer	0.000956	0.00276	CbGpPWpGaD
Metoclopramide—Dizziness—Doxorubicin—thyroid cancer	0.000954	0.00152	CcSEcCtD
Metoclopramide—DRD2—GPCR downstream signaling—CALCB—thyroid cancer	0.000938	0.00271	CbGpPWpGaD
Metoclopramide—Nausea—Epirubicin—thyroid cancer	0.000926	0.00148	CcSEcCtD
Metoclopramide—CHRM1—GPCR downstream signaling—CALCB—thyroid cancer	0.000918	0.00265	CbGpPWpGaD
Metoclopramide—Rash—Doxorubicin—thyroid cancer	0.00091	0.00145	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—thyroid cancer	0.000909	0.00145	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000907	0.00262	CbGpPWpGaD
Metoclopramide—Headache—Doxorubicin—thyroid cancer	0.000904	0.00144	CcSEcCtD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000903	0.00261	CbGpPWpGaD
Metoclopramide—Nausea—Doxorubicin—thyroid cancer	0.000857	0.00137	CcSEcCtD
Metoclopramide—DRD3—GPCR ligand binding—PTCH1—thyroid cancer	0.000853	0.00247	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CALCB—thyroid cancer	0.000851	0.00246	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000848	0.00245	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TSHR—thyroid cancer	0.000833	0.00241	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CALCB—thyroid cancer	0.000833	0.00241	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PRKAR1A—thyroid cancer	0.00082	0.00237	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000784	0.00227	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MEN1—thyroid cancer	0.000783	0.00227	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—SST—thyroid cancer	0.000781	0.00226	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—TSHR—thyroid cancer	0.000768	0.00222	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000768	0.00222	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—TSHR—thyroid cancer	0.000752	0.00217	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CALCA—thyroid cancer	0.000751	0.00217	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—PPARG—thyroid cancer	0.000746	0.00216	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TPR—thyroid cancer	0.000745	0.00216	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PRKAR1A—thyroid cancer	0.000733	0.00212	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTCH1—thyroid cancer	0.000709	0.00205	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—BRAF—thyroid cancer	0.000691	0.002	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000664	0.00192	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CALCB—thyroid cancer	0.000657	0.0019	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—PTCH1—thyroid cancer	0.000653	0.00189	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SST—thyroid cancer	0.000648	0.00187	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TPR—thyroid cancer	0.000642	0.00186	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—PTCH1—thyroid cancer	0.000639	0.00185	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PRKAR1A—thyroid cancer	0.000632	0.00183	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CALCA—thyroid cancer	0.000624	0.0018	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TRIM33—thyroid cancer	0.000623	0.0018	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TPR—thyroid cancer	0.000601	0.00174	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000597	0.00173	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—SST—thyroid cancer	0.000597	0.00173	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PRKAR1A—thyroid cancer	0.000591	0.00171	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—SST—thyroid cancer	0.000585	0.00169	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CALCA—thyroid cancer	0.000575	0.00166	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000573	0.00166	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—PPARG—thyroid cancer	0.000571	0.00165	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—TSHR—thyroid cancer	0.000567	0.00164	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CDK1—thyroid cancer	0.000565	0.00163	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CALCA—thyroid cancer	0.000563	0.00163	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—PPARG—thyroid cancer	0.000559	0.00162	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—SLC5A5—thyroid cancer	0.000558	0.00161	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000536	0.00155	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000523	0.00151	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—TSHR—thyroid cancer	0.000515	0.00149	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—PTEN—thyroid cancer	0.000512	0.00148	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000507	0.00147	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CALCB—thyroid cancer	0.000503	0.00145	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CALCB—thyroid cancer	0.000492	0.00142	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—SLC5A5—thyroid cancer	0.000481	0.00139	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TRIM33—thyroid cancer	0.000477	0.00138	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—RXRA—thyroid cancer	0.000469	0.00136	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TRIM33—thyroid cancer	0.000467	0.00135	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000456	0.00132	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NRG1—thyroid cancer	0.000453	0.00131	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.00045	0.0013	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—SLC5A5—thyroid cancer	0.00045	0.0013	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—SST—thyroid cancer	0.000441	0.00128	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.000439	0.00127	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PTCH1—thyroid cancer	0.000438	0.00127	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—NRAS—thyroid cancer	0.000434	0.00126	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—TSHR—thyroid cancer	0.000434	0.00126	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—TSHR—thyroid cancer	0.000425	0.00123	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CALCA—thyroid cancer	0.000425	0.00123	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000421	0.00122	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TCF7L1—thyroid cancer	0.000416	0.0012	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TERT—thyroid cancer	0.000407	0.00118	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—RXRA—thyroid cancer	0.000404	0.00117	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—SST—thyroid cancer	0.000401	0.00116	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—TSHR—thyroid cancer	0.000394	0.00114	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000393	0.00114	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—PTEN—thyroid cancer	0.000392	0.00113	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HIF1A—thyroid cancer	0.000389	0.00113	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000388	0.00112	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—TSHR—thyroid cancer	0.000386	0.00112	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CALCA—thyroid cancer	0.000386	0.00112	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—PTEN—thyroid cancer	0.000383	0.00111	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00038	0.0011	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—RXRA—thyroid cancer	0.000378	0.00109	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—KRAS—thyroid cancer	0.000374	0.00108	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NDUFA13—thyroid cancer	0.000373	0.00108	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000367	0.00106	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CHST14—thyroid cancer	0.000351	0.00101	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TP53—thyroid cancer	0.000349	0.00101	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CDK1—thyroid cancer	0.000349	0.00101	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—NRAS—thyroid cancer	0.000343	0.000992	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—SST—thyroid cancer	0.000338	0.000976	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PTCH1—thyroid cancer	0.000335	0.00097	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—SST—thyroid cancer	0.00033	0.000956	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PTCH1—thyroid cancer	0.000328	0.000949	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CALCA—thyroid cancer	0.000325	0.00094	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000324	0.000937	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—BRAF—thyroid cancer	0.000322	0.000932	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TCF7L1—thyroid cancer	0.000318	0.00092	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CALCA—thyroid cancer	0.000318	0.00092	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TCF7L1—thyroid cancer	0.000311	0.000901	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—SST—thyroid cancer	0.000307	0.000887	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TSHR—thyroid cancer	0.000304	0.00088	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—SST—thyroid cancer	0.0003	0.000868	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PRKAR1A—thyroid cancer	0.000299	0.000866	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PPARG—thyroid cancer	0.000296	0.000856	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—KRAS—thyroid cancer	0.000295	0.000854	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CALCA—thyroid cancer	0.000295	0.000854	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CALCA—thyroid cancer	0.000289	0.000835	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MEN1—thyroid cancer	0.000286	0.000828	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HPGD—thyroid cancer	0.000283	0.000818	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000279	0.000807	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TP53—thyroid cancer	0.000267	0.000773	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CDK1—thyroid cancer	0.000267	0.000773	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—thyroid cancer	0.000262	0.000757	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CDK1—thyroid cancer	0.000261	0.000756	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTCH1—thyroid cancer	0.000259	0.000748	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PPARG—thyroid cancer	0.000255	0.000738	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HRAS—thyroid cancer	0.000251	0.000726	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AKT1—thyroid cancer	0.000244	0.000706	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PPARG—thyroid cancer	0.000239	0.00069	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000237	0.000686	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SST—thyroid cancer	0.000237	0.000685	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCND1—thyroid cancer	0.000235	0.00068	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TSHR—thyroid cancer	0.000233	0.000674	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTGS2—thyroid cancer	0.000233	0.000673	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000229	0.000663	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TSHR—thyroid cancer	0.000228	0.000659	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CALCA—thyroid cancer	0.000228	0.000659	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTEN—thyroid cancer	0.000227	0.000657	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000224	0.000649	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AKT1—thyroid cancer	0.000221	0.000641	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MEN1—thyroid cancer	0.000219	0.000633	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MEN1—thyroid cancer	0.000214	0.00062	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDK1—thyroid cancer	0.000206	0.000596	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTEN—thyroid cancer	0.000203	0.000587	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NRAS—thyroid cancer	0.000203	0.000586	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTGS2—thyroid cancer	0.000201	0.00058	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTCH1—thyroid cancer	0.000198	0.000573	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTCH1—thyroid cancer	0.000194	0.000561	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—thyroid cancer	0.000188	0.000543	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SST—thyroid cancer	0.000181	0.000524	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SST—thyroid cancer	0.000177	0.000513	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTEN—thyroid cancer	0.000175	0.000506	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KRAS—thyroid cancer	0.000174	0.000504	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CALCA—thyroid cancer	0.000174	0.000504	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CALCA—thyroid cancer	0.000171	0.000493	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NRG1—thyroid cancer	0.000166	0.000479	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTEN—thyroid cancer	0.000164	0.000473	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TPR—thyroid cancer	0.000162	0.00047	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	0.00016	0.000462	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDK1—thyroid cancer	0.000158	0.000456	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—thyroid cancer	0.000155	0.000448	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDK1—thyroid cancer	0.000154	0.000447	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TERT—thyroid cancer	0.000149	0.00043	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—thyroid cancer	0.000148	0.000429	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HIF1A—thyroid cancer	0.000142	0.000411	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—thyroid cancer	0.000131	0.000378	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRG1—thyroid cancer	0.000127	0.000366	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—NRAS—thyroid cancer	0.000125	0.000362	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRG1—thyroid cancer	0.000124	0.000359	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC5A5—thyroid cancer	0.000122	0.000352	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—BRAF—thyroid cancer	0.000118	0.00034	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—thyroid cancer	0.000117	0.000338	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TERT—thyroid cancer	0.000114	0.000329	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TERT—thyroid cancer	0.000111	0.000322	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HIF1A—thyroid cancer	0.000109	0.000315	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—thyroid cancer	0.000108	0.000312	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HIF1A—thyroid cancer	0.000106	0.000308	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—RXRA—thyroid cancer	0.000102	0.000296	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—thyroid cancer	0.000101	0.000292	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—NRAS—thyroid cancer	9.58e-05	0.000277	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—thyroid cancer	9.43e-05	0.000273	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—NRAS—thyroid cancer	9.38e-05	0.000271	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—thyroid cancer	9.16e-05	0.000265	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—BRAF—thyroid cancer	9.01e-05	0.000261	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—thyroid cancer	8.91e-05	0.000258	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—BRAF—thyroid cancer	8.81e-05	0.000255	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—thyroid cancer	8.59e-05	0.000248	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—thyroid cancer	8.29e-05	0.00024	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—thyroid cancer	8.25e-05	0.000239	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—thyroid cancer	8.09e-05	0.000234	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—thyroid cancer	8.07e-05	0.000233	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NRAS—thyroid cancer	7.4e-05	0.000214	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—thyroid cancer	7.01e-05	0.000203	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—thyroid cancer	6.86e-05	0.000198	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	6.82e-05	0.000197	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—thyroid cancer	6.67e-05	0.000193	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—thyroid cancer	6.57e-05	0.00019	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARG—thyroid cancer	6.45e-05	0.000187	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—thyroid cancer	6.43e-05	0.000186	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—thyroid cancer	6.37e-05	0.000184	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—thyroid cancer	6.34e-05	0.000184	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—thyroid cancer	6.21e-05	0.00018	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—thyroid cancer	6.19e-05	0.000179	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—thyroid cancer	6.06e-05	0.000175	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRAS—thyroid cancer	5.66e-05	0.000164	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—thyroid cancer	5.66e-05	0.000164	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRAS—thyroid cancer	5.54e-05	0.00016	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—thyroid cancer	5.41e-05	0.000157	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—thyroid cancer	5.07e-05	0.000147	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—thyroid cancer	4.87e-05	0.000141	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—thyroid cancer	4.78e-05	0.000138	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—thyroid cancer	4.77e-05	0.000138	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—thyroid cancer	4.43e-05	0.000128	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—thyroid cancer	4.33e-05	0.000125	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—thyroid cancer	4.24e-05	0.000123	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—thyroid cancer	4.14e-05	0.00012	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—thyroid cancer	4.05e-05	0.000117	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—thyroid cancer	3.66e-05	0.000106	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—thyroid cancer	3.58e-05	0.000104	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—thyroid cancer	2.55e-05	7.38e-05	CbGpPWpGaD
